Elicio Therapeutics (ELTX) Other financing activities (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Other financing activities for 7 consecutive years, with $17000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities changed N/A year-over-year to $17000.0; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (up 191.53% YoY), and the FY2025 full-year result was $1.3 million, down 78.4% from the prior year.
• Other financing activities fell to $17000.0 in Q2 2026 per ELTX's latest filing, from $100000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $16.9 million in Q3 2024 and bottomed at -$16.9 million in Q4 2024.
• Historically, Other financing activities has averaged $584923.1 across 5 years, with a median of $65000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Other financing activities sank 710.0% in 2022, then soared 28100.0% in 2024.
• Over 5 years, Other financing activities stood at $65000.0 in 2022, then declined by 7.69% to $60000.0 in 2023, then plunged by 28261.67% to -$16.9 million in 2024, then jumped by 105.62% to $950000.0 in 2025, then plunged by 98.21% to $17000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $17000.0, $100000.0, and $950000.0 for Q2 2026, Q1 2026, and Q3 2025 respectively.